https://thelifesciencefeed.com/rheumatology/sjogren-syndrome/research/sjogren-s-disease-new-therapies-target-underlying-immune-pathways The Life Science Feed en 2026-08-27T00:00:00Z Sjögren's Disease: New Therapies Target Underlying Immune Pathways https://thelifesciencefeed.com/rheumatology/sjogren-syndrome/practice/sjogren-s-disease-early-damage-often-present-at-diagnosis The Life Science Feed en 2026-08-27T00:00:00Z Sjögren's Disease: Early Damage Often Present at Diagnosis https://thelifesciencefeed.com/rheumatology/sjogren-syndrome/insights/sjogren-s-disease-bridging-the-5-year-diagnostic-gap-to-emerging-therapies The Life Science Feed en 2026-08-27T00:00:00Z Sjögren's Disease: Bridging the 5-Year Diagnostic Gap to Emerging Therapies https://thelifesciencefeed.com/oncology/radioligand-therapy/practice/navigating-psma-rlt-for-prostate-cancer-what-clinicians-need-to-know-now The Life Science Feed en 2026-08-27T00:00:00Z Navigating PSMA-RLT for Prostate Cancer: What Clinicians Need to Know Now https://thelifesciencefeed.com/oncology/cervical-neoplasms/practice/adding-pembrolizumab-to-chemotherapy-extends-survival-in-advanced-cervical-cancer The Life Science Feed en 2026-08-27T00:00:00Z Adding Pembrolizumab to Chemotherapy Extends Survival in Advanced Cervical Cancer https://thelifesciencefeed.com/oncology/antibody-drug-conjugates/research/managing-trastuzumab-deruxtecan-dosing-and-adverse-event-insights The Life Science Feed en 2026-08-27T00:00:00Z Managing Trastuzumab Deruxtecan: Dosing and Adverse Event Insights https://thelifesciencefeed.com/oncology/cervical-neoplasms/insights/cervical-cancer-elimination-why-income-isn-t-the-only-barrier The Life Science Feed en 2026-08-27T00:00:00Z Cervical Cancer Elimination: Why Income Isn't the Only Barrier https://thelifesciencefeed.com/oncology/gastric-neoplasms/practice/her2-heterogeneity-why-single-block-testing-may-miss-gastric-cancer-treatment-targets The Life Science Feed en 2026-08-27T00:00:00Z HER2 Heterogeneity: Why Single-Block Testing May Miss Gastric Cancer Treatment Targets https://thelifesciencefeed.com/oncology/antibody-drug-conjugates/insights/trastuzumab-deruxtecan-reshapes-her2-low-metastatic-breast-cancer-treatment The Life Science Feed en 2026-08-27T00:00:00Z Trastuzumab Deruxtecan Reshapes HER2-Low Metastatic Breast Cancer Treatment https://thelifesciencefeed.com/oncology/immune-checkpoint-inhibitors/insights/two-year-checkpoint-inhibitor-therapy-is-it-enough-for-advanced-nsclc The Life Science Feed en 2026-08-27T00:00:00Z Two-Year Checkpoint Inhibitor Therapy: Is It Enough for Advanced NSCLC? https://thelifesciencefeed.com/oncology/radioligand-therapy/insights/radioligand-therapy-is-capacity-not-efficacy-limiting-patient-access The Life Science Feed en 2026-08-27T00:00:00Z Radioligand Therapy: Is Capacity, Not Efficacy, Limiting Patient Access? https://thelifesciencefeed.com/oncology/car-t-cell-therapy/insights/cilta-cel-extends-overall-survival-in-lenalidomide-refractory-multiple-myeloma The Life Science Feed en 2026-08-27T00:00:00Z Cilta-cel Extends Overall Survival in Lenalidomide-Refractory Multiple Myeloma https://thelifesciencefeed.com/oncology/endometrial-neoplasms/practice/refining-endometrial-cancer-prognosis-when-pole-mutations-truly-matter The Life Science Feed en 2026-08-27T00:00:00Z Refining Endometrial Cancer Prognosis: When POLE Mutations Truly Matter https://thelifesciencefeed.com/oncology/biliary-tract-neoplasms/insights/kras-mutations-signal-poorer-outcomes-in-biliary-tract-cancers The Life Science Feed en 2026-08-27T00:00:00Z KRAS Mutations Signal Poorer Outcomes in Biliary Tract Cancers https://thelifesciencefeed.com/oncology/gastric-neoplasms/insights/flot-regimen-extends-survival-in-resectable-gastric-adenocarcinoma The Life Science Feed en 2026-08-27T00:00:00Z FLOT Regimen Extends Survival in Resectable Gastric Adenocarcinoma https://thelifesciencefeed.com/oncology/biliary-tract-neoplasms/practice/targeted-therapies-extend-survival-in-advanced-cholangiocarcinoma The Life Science Feed en 2026-08-27T00:00:00Z Targeted Therapies Extend Survival in Advanced Cholangiocarcinoma https://thelifesciencefeed.com/oncology/car-t-cell-therapy/research/car-t-cell-therapy-and-secondary-t-cell-malignancies-what-the-data-reveal The Life Science Feed en 2026-08-27T00:00:00Z CAR T-Cell Therapy and Secondary T-Cell Malignancies: What the Data Reveal https://thelifesciencefeed.com/oncology/immune-checkpoint-inhibitors/research/perioperative-immunotherapy-for-resectable-nsclc-a-comparative-review-protocol The Life Science Feed en 2026-08-27T00:00:00Z Perioperative Immunotherapy for Resectable NSCLC: A Comparative Review Protocol https://thelifesciencefeed.com/oncology/immune-checkpoint-inhibitors/practice/immune-checkpoint-inhibitor-myocarditis-a-rare-high-mortality-risk The Life Science Feed en 2026-08-27T00:00:00Z Immune Checkpoint Inhibitor Myocarditis: A Rare, High-Mortality Risk https://thelifesciencefeed.com/oncology/cervical-neoplasms/research/pembrolizumab-improves-overall-survival-in-locally-advanced-cervical-cancer The Life Science Feed en 2026-08-27T00:00:00Z Pembrolizumab Improves Overall Survival in Locally Advanced Cervical Cancer https://thelifesciencefeed.com/oncology/antibody-drug-conjugates/practice/antibody-drug-conjugates-the-evolving-role-in-breast-cancer-management The Life Science Feed en 2026-08-27T00:00:00Z Antibody-Drug Conjugates: The Evolving Role in Breast Cancer Management https://thelifesciencefeed.com/oncology/gastric-neoplasms/research/zolbetuximab-a-new-first-line-option-for-cldn18-2-positive-gastric-cancer The Life Science Feed en 2026-08-27T00:00:00Z Zolbetuximab: A New First-Line Option for CLDN18.2-Positive Gastric Cancer? https://thelifesciencefeed.com/oncology/endometrial-neoplasms/guidelines/immunotherapy-reshapes-first-line-treatment-for-advanced-endometrial-cancer The Life Science Feed en 2026-08-27T00:00:00Z Immunotherapy Reshapes First-Line Treatment for Advanced Endometrial Cancer https://thelifesciencefeed.com/oncology/radioligand-therapy/research/when-to-use-177lu-psma-617-in-metastatic-prostate-cancer-before-or-after-taxanes The Life Science Feed en 2026-08-27T00:00:00Z When to use 177Lu-PSMA-617 in metastatic prostate cancer: before or after taxanes? https://thelifesciencefeed.com/oncology/car-t-cell-therapy/practice/car-t-neurotoxicity-beyond-icans-and-the-transplant-center The Life Science Feed en 2026-08-27T00:00:00Z CAR-T Neurotoxicity: Beyond ICANS and the Transplant Center https://thelifesciencefeed.com/oncology/endometrial-neoplasms/research/dostarlimab-plus-chemotherapy-extends-progression-free-survival-in-advanced-endometrial-ca The Life Science Feed en 2026-08-27T00:00:00Z Dostarlimab Plus Chemotherapy Extends Progression-Free Survival in Advanced Endometrial Cancer https://thelifesciencefeed.com/oncology/biliary-tract-neoplasms/research/durvalumab-plus-chemotherapy-a-new-first-line-option-for-advanced-biliary-tract-cancer The Life Science Feed en 2026-08-27T00:00:00Z Durvalumab Plus Chemotherapy: A New First-Line Option for Advanced Biliary Tract Cancer? https://thelifesciencefeed.com/rheumatology/inflammatory-myopathies/research/myositis-specific-autoantibodies-prognosis-screening The Life Science Feed en 2026-08-27T00:00:00Z Myositis-Specific Autoantibodies: Predicting Prognosis and Guiding Screening https://thelifesciencefeed.com/neurology/huntington-disease/insights/managing-chorea-balancing-tetrabenazine-deutetrabenazine-and-psychiatric-risk The Life Science Feed en 2026-08-27T00:00:00Z Managing chorea: balancing tetrabenazine, deutetrabenazine and psychiatric risk